Home
CORT
CORT News

Latest Corcept Therapeutics Incorporated (CORT) News on July 1, 2025

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Zacks

3 days ago

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

5 Insightful Analyst Questions From Corcept’s Q1 Earnings Call

StockStory

4 days ago

5 Insightful Analyst Questions From Corcept’s Q1 Earnings Call

Argus Research

6 days ago

CORT: Raising target price to $84.00

Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint

Insider Monkey

6 days ago

Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

Business Wire

7 days ago

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

June 2025's High Insider Ownership Growth Stocks

Simply Wall St.

8 days ago

June 2025's High Insider Ownership Growth Stocks

Do Its Financials Have Any Role To Play In Driving Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Up Recently?

Simply Wall St.

8 days ago

Do Its Financials Have Any Role To Play In Driving Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Up Recently?

Argus Research

20 days ago

CORT: Raising target price to $79.00

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study

Benzinga

25 days ago

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study

MT Newswires

a month ago

Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

Business Wire

a month ago

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

MT Newswires

a month ago

Corcept Therapeutics Insider Sold Shares Worth $1,581,687, According to a Recent SEC Filing

MT Newswires

a month ago

Corcept Therapeutics Insider Sold Shares Worth $3,314,310, According to a Recent SEC Filing

2 Profitable Stocks to Target This Week and 1 to Avoid

StockStory

a month ago

2 Profitable Stocks to Target This Week and 1 to Avoid

Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?

Zacks

a month ago

Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday

Insider Monkey

a month ago

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday

Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment

Simply Wall St.

a month ago

Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment

MT Newswires

a month ago

Corcept Therapeutics Says Relacorilant Met Primary Endpoint in Phase 3 Ovarian Cancer Trial

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Business Wire

a month ago

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

1 Cash-Heavy Stock on Our Watchlist and 2 to Steer Clear Of

StockStory

a month ago

1 Cash-Heavy Stock on Our Watchlist and 2 to Steer Clear Of

New Strong Sell Stocks for May 29th

Zacks

a month ago

New Strong Sell Stocks for May 29th

1 Growth Stock with All-Star Potential and 2 to Avoid

StockStory

a month ago

1 Growth Stock with All-Star Potential and 2 to Avoid

Discover 3 Growth Stocks With Insider Ownership Up To 28%

Simply Wall St.

a month ago

Discover 3 Growth Stocks With Insider Ownership Up To 28%

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

StockStory

a month ago

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

MT Newswires

a month ago

Corcept Therapeutics Insider Sold Shares Worth $2,030,453, According to a Recent SEC Filing

MT Newswires

a month ago

Corcept Therapeutics Insider Sold Shares Worth $2,393,014, According to a Recent SEC Filing

Argus Research

a month ago

CORT: Raising target price to $84.00

CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed

StockStory

a month ago

CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed

Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

StockStory

2 months ago

Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

Argus Research

2 months ago

CORT: What does Argus have to say about CORT?

Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Simply Wall St.

2 months ago

Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now

Insider Monkey

2 months ago

Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now

1 Small-Cap Stock Worth Your Attention and 2 to Question

StockStory

2 months ago

1 Small-Cap Stock Worth Your Attention and 2 to Question

Corcept Therapeutics price target lowered to $135 from $150 at Truist

TipRanks

2 months ago

Corcept Therapeutics price target lowered to $135 from $150 at Truist

Argus Research

2 months ago

CORT: Lowering target price to $78.00

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Corcept Therapeutics Inc Earnings Call

Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS

Simply Wall St.

2 months ago

Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS

CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall

Zacks

2 months ago

CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall

MT Newswires

2 months ago

Corcept Therapeutics Insider Sold Shares Worth $2,915,922, According to a Recent SEC Filing

MT Newswires

2 months ago

Corcept Therapeutics Insider Sold Shares Worth $2,842,769, According to a Recent SEC Filing

Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ...

GuruFocus.com

2 months ago

Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ...

Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates

Zacks

2 months ago

Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates

Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops

StockStory

2 months ago

Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops

MT Newswires

2 months ago

Corcept Therapeutics Q1 Earnings Decrease, Revenue Rises -- Shares Fall After Hours

Associated Press Finance

2 months ago

Corcept: Q1 Earnings Snapshot

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Business Wire

2 months ago

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

Insider Monkey

2 months ago

Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect

StockStory

2 months ago

Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect

Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years?

Insider Monkey

2 months ago

Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years?

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?

Zacks

2 months ago

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

Business Wire

2 months ago

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

3 Healthcare Stocks That Concern Us

StockStory

2 months ago

3 Healthcare Stocks That Concern Us

3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth

Simply Wall St.

2 months ago

3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey

2 months ago

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

Business Wire

2 months ago

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

Argus Research

2 months ago

CORT: Lowering target price to $71.00

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Business Wire

2 months ago

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Argus Research

3 months ago

CORT: Lowering target price to $76.00

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter

Simply Wall St.

3 months ago

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter

Argus Research

3 months ago

CORT: Lowering target price to $78.00

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Business Wire

3 months ago

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

MT Newswires

3 months ago

Corcept Therapeutics Insider Sold Shares Worth $10,121,594, According to a Recent SEC Filing

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks

3 months ago

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?

Zacks

3 months ago

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?

Argus Research

3 months ago

CORT: Raising target price to $120.00

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

TipRanks

3 months ago

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal

Zacks

3 months ago

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal

Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?

Zacks

3 months ago

Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?

Insider Monkey

3 months ago

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?

Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement

Clinical Trials Arena

3 months ago

Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement

MT Newswires

3 months ago

Equity Markets Mixed Ahead of Tariff Announcements

Why Is Corcept (CORT) Stock Soaring Today

StockStory

3 months ago

Why Is Corcept (CORT) Stock Soaring Today

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

Simply Wall St.

3 months ago

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

MT Newswires

3 months ago

Top Midday Gainers

NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute

Yahoo Finance Video

3 months ago

NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute

MT Newswires

3 months ago

Piper Sandler Raises Corcept Therapeutics' Price Target to $128 From $78, Maintains Overweight Rating

MT Newswires

3 months ago

Sector Update: Health Care Stocks Fall Pre-Bell Monday

MT Newswires

3 months ago

Sector Update: Health Care

MT Newswires

3 months ago

Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Business Wire

3 months ago

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?

Zacks

3 months ago

Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?

3 Reasons to Sell CORT and 1 Stock to Buy Instead

StockStory

3 months ago

3 Reasons to Sell CORT and 1 Stock to Buy Instead

Argus Research

3 months ago

CORT: Raising target price to $76.00

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?

Zacks

3 months ago

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?

3 Growth Stocks in Hot Water

StockStory

3 months ago

3 Growth Stocks in Hot Water

1 Small-Cap Stock on Our Buy List and 2 to Avoid

StockStory

4 months ago

1 Small-Cap Stock on Our Buy List and 2 to Avoid

Top Growth Companies With Significant Insider Ownership

Simply Wall St.

4 months ago

Top Growth Companies With Significant Insider Ownership

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Business Wire

4 months ago

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Zacks

4 months ago

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?

Zacks

4 months ago

Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?

Corcept Therapeutics' (NASDAQ:CORT) Earnings Offer More Than Meets The Eye

Simply Wall St.

4 months ago

Corcept Therapeutics' (NASDAQ:CORT) Earnings Offer More Than Meets The Eye

Argus Research

4 months ago

CORT: Lowering target price to $59.00

Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

4 months ago

Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

StockStory

4 months ago

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

StockStory

4 months ago

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

MT Newswires

4 months ago

Corcept Therapeutics Says New Drug Application for Cushing's Syndrome Treatment Filed by FDA

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Business Wire

4 months ago

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)

Zacks

4 months ago

3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)

Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?

Zacks

4 months ago

Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 48% Above Its Share Price

Simply Wall St.

4 months ago

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 48% Above Its Share Price

Share on Social Networks: